The present disclosure relates to, inter alia, a formulation comprising one or more active agents and one or more thermal stabilizing agents and is co-mingled with a first propellant that is a gas propellant prior to being filled under pressure into said package; the first propellant is added in sufficient amounts to be dispersed in the formulation; the package is under sufficient pressure suitable to expel the formulation as a whipped formulation upon application of external force on said formulation in said package. The present disclosure also relates to, inter alia, a method of preparing the disclosed formulation; a package comprising the disclosed formulation, and a method of using the disclosed formulation.

The present disclosure relates to, inter alia, a gel formulation in a package, the package may be pressurized. The formulation comprises one or more active agents and is co-mingled with a gas propellant prior to being filled under pressure into the package. The gas propellant is added in sufficient amounts to be dispersed in the formulation; the pressurized package is under sufficient pressure suitable to maintain the first gas propellant dispersed in the formulation. The pressurized package is under sufficient pressure to expel the formulation as a whipped gel formulation upon application of external force on the formulation in the package. The present disclosure also relates to, inter alia, a method of preparing the disclosed formulation; a package comprising the disclosed formulation, and a method of using the disclosed formulation.

A method for alleviating ultraviolet damage includes administering to a subject in need thereof a composition containing an ethyl acetate-extracted product of Sedum formosanum. The ethyl acetate-extracted product of Sedum formosanum is prepared by a process including the steps of (a) extracting Sedum formosanum with methanol to obtain a methanol-extracted product from Sedum formosanum; (b) partitioning the methanol-extracted product with water and n-hexane to obtain an aqueous layer and a n-hexane layer; and (c) partitioning the aqueous layer obtained in step (b) with ethyl acetate, followed by collecting an ethyl acetate layer thus formed to obtain the ethyl acetate-extracted product of Sedum formosanum.

A method for at least one of whitening skin, improving skin condition, protecting skin, and treating skin disease is provided, wherein the method comprises administering to a subject in need an effective amount of a Pyrenaria buisanensis extract. A method for at least one of preventing cardiovascular disease, treating cardiovascular disease, preventing diabetes, treating diabetes, preventing neurodegenerative disease, and treating neurodegenerative disease is also provided, wherein the method comprises administering to a subject in need an effective amount of a Pyrenaria buisanensis extract.

The present invention relates to compositions and methods of using free radical scavengers with reduced .sup.1O.sub.2 generation. In certain embodiments, these compositions and methods of use relate to fullerene-derived ketolactams and fullerene-derived ketolactam derivatives, fullerene derivatives, and/or fullerenes. In yet other embodiments, the invention relates to cosmetic or dermatological compositions comprising said free radical scavengers with reduced .sup.1O.sub.2 generation.

The present invention relates to a topical composition comprising one or more compounds of formula (I), wherein X is hydrogen or a glycosyl moiety, the carbon-carbon bond noted is a double or a single bond, R.sup.1 is an alkyl chain having 10-20 carbon atoms, R.sup.2 is hydrogen or a substituted or unsubstituted acyl having 16-34 carbon atoms, R.sup.3 is hydrogen when the carbon-carbon bond noted is a double or a single bond, and R.sup.3 is OH when the carbon-carbon bond noted is a single bond, R.sup.4 is hydrogen when the carbon-carbon bond noted is a double or a single bond, and R.sup.4 is hydrogen or OH when the carbon-carbon bond noted is a double bond, said composition is characterized in that at least one of the one or more compounds of formula (I) has a lactosyl moiety or a glucosyl moiety in the position X.

##STR00001##

Disclosed are certified natural skin compositions and related methods of use. Certified natural compositions include diaper rash compositions, antioxidant sunscreen compositions, with or without natural sparkle or shimmer ingredient(s), and after-sun, tan-enhancing bronzer, skin toner or moisturizer composition with natural sparkle or shimmer. The inventive natural skin compositions are specifically formulated with natural ingredients, such that the products are suitable for certification as natural and/or organic products, and more particularly formulated with a variety of high-quality ingredients that care for and protect skin.

The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Peptide and/or peptide derivative antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity are described. Also described are peptide and/or peptide derivative antagonists exhibiting Simul-Block activity, and inhibiting the activity of multiple ?c-cytokine family members.

Embodiments relate to peptide antagonists of -family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of -cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual -cytokine family member/ receptor subunit. However, success has been limited and often multiple -cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus -subunit binding site to inhibit -cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple -cytokine family members.

One variation of a method includes: accessing a skin type of a user; predicting a first set of locations occupied by the user during a first future time interval; based on historical ultraviolet irradiance data and the first future time interval, calculating a first predicted unprotected ultraviolet radiation exposure of the user during the first future time interval; calculating a maximum allowable ultraviolet radiation exposure for periods within the first future time interval based on the skin type of the user; calculating a first minimum sun protection factor predicted to reduce the first predicted unprotected ultraviolet radiation exposure to less than the maximum allowable ultraviolet radiation exposure; selecting a first sunscreen formula characterized by a first sun protection factor greater than the first minimum sun protection factor; and shipping the first volume of the first sunscreen formula to the user prior to the first future time interval.